BioSig AI Sciences raises $495k via private placement; BioSig retains 84.5% ownership

Streamex Corp.

BioSig subsidiary BioSig AI Sciences issued 495,000 shares at $1.00 each to institutional/accredited investors.
BioSig Technologies retains approximately 84.5% ownership of BioSig AI after the closing.
Laidlaw & Company (UK) Ltd. received a warrant for 40,500 shares at $1.00 per share, expiring in 5 years.
Shares and warrant are unregistered, sold under Section 4(a)(2) and Regulation D.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Streamex Corp. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at $495,000 (effective 2023-07-19).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and accredited investors
Value: $495,000
Effective: 2023-07-19

Exact text from the filing

On July 19, 2023, BioSig AI Sciences, Inc., f/k/a NeuroClear Technologies Inc. (“BioSig AI”), a subsidiary of BioSig Technologies, Inc. (“BioSig”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which BioSig AI agreed to sell an aggregate of 495,000 shares (the “Shares”) of BioSig AI’s common stock, par value $0.001 per share (the “Common Stock”) for an aggregate purchase price of $495,000

View on SEC.gov

277 material agreements filed in the last 30 days. Browse all material agreements →

Streamex Corp. filing history →

Source: SEC EDGAR

accession 0001185185-23-000751

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.